Drug updated on 11/8/2023
|Capsule (oral; 150 mg)
|Hedgehog pathway inhibitors
| Ongoing and
- For the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.
Product Monograph / Prescribing Information
|Erivedge (vismodegib) Prescribing Information
|Genentech USA, Inc., South San Francisco, CA
Systematic Reviews / Meta-Analyses
|Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009–2022).
|American Journal of Clinical Dermatology
|Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: a systematic review and meta-analysis.
|Journal of the American Academy of Dermatology
Clinical Practice Guidelines
|Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines.
|European Journal of Cancer
|A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors
|Guidelines of care for the management of basal cell carcinoma.
|American Academy of Dermatology